parasites which we find in an epidemiologic survey represents a relatively constant breach of environmental hygiene.
In an epidemic outbreak of disease wherein we assume that there is a single strain of virulent parasite which is operative, tile ratio of clinical illness to carrier state is still remarkably low. Tile best illustration of this is the outbreak of amebiasis that occurred in South Bend, Indiana (2) . A careful epidemiologic study of the group at risk was carried out. There were 800
isolates of E histol),tica among the population of South Bend that could have been affected, but only 31 clinical cases of amebiasis. There were 2 liver abscesses and 4 deaths in that particular epidemic, hence the impression that the ratio of clinical disease to carrier state is low even with a virulent parasite.
In addition to epidemic experience, we observe tile steady but infrequent appearance of single cases of clinically significant systemic amebiasis, usually liver abscess. These are truly indigenous cases. They turn up at the University of Michigan at the rate of about one a year. The last one we had was a 25-year-old musician from the Ann Arbor-Ypsilanti area wlto presented with weight loss, right upper quadrant discomfort and night sweats. His only history of travel was a visit to New York State. He had not been out of the country or to the Southern United States. His illness was prolonged, and at the time he was seen, he had been sick for 3 months. A month before he came to the University of Michigan he had been hospitalized in New York City with similar though somewhat less marked complaints and had been released without a diagnosis, tte gave no history of dysentery or diarrhea. If anything, he felt that he had had some constipation in the recent past. Physical findings were linfited to a remarkable hepatomegaly with liver tenderness. Barium studies were not helpful. Liver function tests showed only mild abnormalities. Scans and selective angiography delineated space-occupying lesions in the liver, which on aspiration, contained typical pus. The patient responded promptly to metronidazole. He encountered some complications later, but has since recovered and has done extremely well.
These sporadic kinds of outbreaks, whether they are epidemics or single cases, keep alive in our own environment the clinical speculation that amebiasis is some kind of sleeping evil which, given the proper circumstance, can be re!eased into the population. There are less frightening alternative observations that can be made in the light of a 2% incidence of ameba.
Intestinal amebiasis presents in several different ways. When there is amebic dysentery, with passage of exudate and blood rather than feces in the stool, the laboratory will report that there are large, motile, red-celt containing trophozoites that hav ~-a characteristic E histolytica nuclear morphology. If there is diarrhea with stools containing exudate and blood in addit.;on to feces and again characteristic ameba on microscopic examination, it is relatively easy to make a diagnos:s of amebic co!itis. Few if any supplementary studies would be necessary before beginning treatment. These presentations are rare in our environment. When a patient presents with symptoms that are nonspecific or fimctional and the laboratory reports only the presence of characteristic cysts, then a diagnosis of a carrier state can be made. The decision to treat the patient may not be ~o easily justified. Most hospital laboratories report the finding of amebae far less tyequently than a 2°/o incidence of infection would suggest they should, in part because cysts in a carrier state may be few in number and may be shed irregularly in the stool, and in part because of unfamiliarity or inexperience in the laboratory. This review of the current status of our understanding of ameba infection will hopefully offer some perspective for deciding how zealously one should look for amebae in any individual and what to do when a carrier is found. This is a story which is still developing and I will try to indicate the areas which remain speculative.
Classically The Amoeba Living In Man, published in 1919. It is this particular document that is carried through the literature to us today. It was Dobell's impression that the ameba, as an obligate cellular parasite, was in a kind of balanced equilibrium with the intestine--ie, cellular disso'.ution was balanced by regeneration and replacement of intestinal tissue. This impression of the ameba as an obligate cellular parasite in equilibrium with its host was strengthened by the failure to establish ameba in an in vitro culture. In 1925, however, a reproducible culture technic was found, and it was seen that ameba could grow in tile al)sence of mammalian ce,ls.
There emerged from these findings a divergence of opinion about the pathogenic potential of amebae, in particular, concerning virulent an(l avirulent strains. Craig and Faust (7), who exemplified an American school of thought, felt that ameba infection always implied a mucosal lesion somewhere in the intestinal tract. A less extreme, but similar view, sometimes called the Unicist school, proposed that at times E histolytica could live as a commensal. (A commensal is defined as a messmate, as someone who eats with you and doesn't eat you.) However, all E histolytica belonged to a single race of potentially pathogenic amebae. The differences in behavior in ameba infections were explained by these investigators as being due to extrinsic factors such as host resistance, diet and the microenvironment in the intestinal tract. This viewpoint remains represented in the standard medicine textbooks to this day (3, 4) . It should be clear that the external environment, the intestinal microenvironment, and the host response play a very fundamental role in the outcome of any experience with E histolytica, but this is distinct from or adds to the question of intrinsic pathogenicity. Elsdon-Dew justifies the role of external factors in South Africa where there is a single pool of ameba to which three culturally distinct groups are exposed. The urban Bantu come down with a fulminating infection, amebic dysentery. The East Indian population presents essentially as carriers and the Europeans in this environment have rather infrequent clinical infections. They all have a relatively heavy common exposure. These Promethean and Unicist schools, as they were called, recognized a single strain of ameba that had a pathogenic potential.
Since Classic E histolytica cannot be maintained in any but an isotonic medium. Dilution of the medium by as little as 1 to 2 with distilled water will cause the cultures to die out. The Laredo-like ameba can not only survive but it can ~-ow in a medium diluted as much as 1 to 64 with distilled water. This offers another differential test that could be used in a bacteriology laboratory.
There are substantial numbers of other biochemical differences between these two amebae. Drug sensitivity studies reveal that the Laredo-like ameba is more resistant to the usual amebacidal drugs than the classic strain. There are quantitative differences in the free amino acid composition and there have been differences demonstrated in the isoenzyme patterns.
In addition to the biochemical differences, there are a number of immunochemical comparisons o[ classic and Lqredo-like amebae. All of them show the presence of shared antigens, but there are a sufficient number of antigenic differences to permit the separation of classic from Laredo-like ameba by immunologic means. The methods of comparison have included fluorescent antibody technics, agar diffusion studies and hemagglutination studies.
Not all information has been in support of differences of the two groups. No difference ill carbohydrate utilization in (u ture has been found. There is a single unpablished report of the laboratory demonstration of exchange of genetic material between amebae of the two groups based on drug resistance as a genetic marker (18) . Presumably, amebae capable of exchanging genetic material cannot be separated as species. It should be noted that the negative studies are unconfirmed and the evidence continues to support the differences between these two groups.
What elevates these apparent biologic differences between classic and Laredo-like ameba to clinical significance are studies of the pathogenicity of the parasite. As indicated, no isolate of Laredo-!ike ameba has clearly come from an individual who suffered acute intestinal or systemic am~bi-asis. All bave come more or less clear!y from carriers. One strain was sqbjecte:l to the most strenuous clinical test of pathogenicity that any ameba has been subiected to. Prior to its identification as a Laredo-like ameba, the Huff strain was selected for a clinical trial of an induced ameba infection in human volunteers (16) . The Huff strain was given to 130 prisoner volunteers by oral ingestion of cysts. Eighty-one of the volunteers were successfully infected, as evidenced by the continuous passage of cysts in their stools. Of the group of 81, no individual was symptomatic in spite of the passage of ameba in the stool. The clinical evaluation of these patients included sigmoidoscopy. A variety of animal inoculations have been carried out with uniform demonstration of a low or negligible pathogenicity of the Laredo-like ameba in all cases. There is some overlap between the classic and Laredo-like ameba strains in terms of their virulence in animals other than man.
Considering the criteria which distin-guish the Laredo-like ameba fronl the classic strain, the differences are substantial enough to suggest that the l.aredo-_ike ameba may be a separate species. This would in effect make then1 the equiwdent of Brumpt's nonpathogenic E dispa.r. This has not been done because of the paucity of isolates of low temperature strains. There have been only six isolates thus far reported. In terms of numbers, the evk!ence is not yet overwhelming enough to perm:t the establishment of a new species. The next step from the clinical standpoint is reasonably clear. The parasitologist has handed the clinician an attractive l)athophysiologic scheme which could explain the clinical appearance of ameba infection; this scheme needs to be validated. In effect, it is ready for clinical trial. An exhaustive re-evaluation of the efficiency of cultural methods for the diagnosis of ameba infections is required. We are currently no mo:e justified in accepting microscopic examination of the stool for the diagnosis of E histolytica than we would be in restricting ourselves solely to the Gram stain of a sputum smear for the diagnosis of pneumonia. Clinical microscopy is useful and has a place in both circumstances, but it may be insufficient when taken alone. As a second step, we will need to identify the biologic characteristics of the amebae that infect at least 1-2% of our local population. if and when it finds this place, one expects that there will remain some infections to treat. Just as there is currently a new understanding that threatens our current concept of clinical amebiasis, there are significant, virtually revolntionary advances in therapy which press in on our established regimens. Here the contest is less emotionally charged, since truly effective therapy of low toxicity, until now, has been lacking. What follows is a review of the efficiency and tolerance of the commonly employed intestinal and sDtemic amebacides to provide the framework within which the new offerings may he judged. As the spectrum of pharmacologic behavior unfolds, the rationale for acceptance of the newer preparations should become much clearer.
Emetine is the baseline drug again:t which other drug activities are measured. It is the oldest known effective amebacide. It has been found useful in both intestinal and systemic ameba infection. Its earliest use was in the treatment of dysentery (19) . An alkaloid extracted from a plant which is indigenous to South America. it was taken to Europe in 1658. It led a rather checkered and secret career, and at one point, was sold to the French government as a secret remedy. It didn't achieve significant use until 1858 and the classic paper describing its effectiveness was that of Leonard Rogers in 1912 (20) . The drug remains in widespread use today.
Emetine affords prompt relief of symptoms in acute amebiasis although it is ineffective in terms of parasito'ogic cure. It seems to be more effective in extraintestinal amebiasis, perhaps because it is concentrated in the liver, which is the usual site of extraintestinal involvement. Representative results in invasive intestinal amebiasis--ie, amebic dysentery--are 5ao¢ /O successes, 28 °: absolute failures and 22~o
,o probable failures (21) . A success is a patient that is symptom-free and parasite-free. An absolute failure is a patient whose symptoms have not improved, and in whom parasites and ulcers in the rectum are still present. A probable failure is a patient whose symptoms have improved but whose ulcers remain.
These results are drawn from the work of the Amebiasis Research Unit in Durban, South Africa (21). Although va.ious amebacides have been widely tested and reported, the subsequent discussion will be based on the data reported by this single unit. The compilation is based on a number of separately published studies, but they have all been performed by a single group of investigators who explicitly attempted to achieve maximum uniformity in their drug test program. They represent, then, the most reliable body of comparative information concerning amebacidal drugs.
The clinical dissatisfaction with emetine steins not only from its rather mediocre performance in terms of parasitologic cure but also from its substantial toxicity. Emetine is a protoplasmic poison with a direct effect on muscular and nervous tissue (22) . It is excreted slowly, and the effect may be cumulative if its administration is too rapid. The incidence of reported untoward reactions is high if the dosage is adequate and the observation complete. In one study, 91 of 96 patients experienced some side effect (23) . Within the safe dose range, one may expect myocardial changes such as increase in heart rate, decrease in systolic pressure and evidence of T wave inversion oil the electrocardiogram (24) . In addition, encephalitis, paralysis and Herxheimer-like reactions have been reported. With this drug as a scale, it is possible to turn to the comparative value of the other common amebacides that we use.
Some classes of drugs are active in intestinal infection; diodoquin (5, 7 diiodo 8 hydroxyquinoline) is representative of the first general category of these. It has low toxicity, most frequently manifested as io-(line sensitivity. It has no better effect than emetine, with 58~' o success, 24~o failure and 18~o probable failure rate (21) . It is a contact or luminal drug. The dose is 0.65 g orally three times daily for 21 days.
Representative of the next class of drugs are the arsenic preparations, carbarsone and Milibus. Carbarsone's dosage is 0.25 g three times a day for 10 days. This is the largest dose which can be tolerated without a prohibitive incidence of reactions. The toxicity is arsenic poisoning and includes nausea, vomiting, convulsions, skin rash, exfoliative dermatitis, cramps, diarrhea and occasionally jaundice (25) . It is not significantly more effective than emetine (21) .
Milibus contains arsenic and bismuth. Its dosage is 0.5 g three times a day for 7 days. The toxicity is generally similar to carbarsone, although the margin of safety may be a little greater (24) . It is substantially less effective than emetine (21) .
Entamide furoate (diloxanide furoate) is not available in this country, but has been widely used in tropical Africa. The do~age is 4 g daily for 10 days. It seems to be an effective drug in both the acute intestinal disease and in the carrier state. Cure rates in some hands have ranged as high as 80~, tltough the South African group's success rate in amebic dysentery was in the range of 40~%. Toxicity is mild--mostly tingling and the development of flatulence. It corn-pares favorably with emetine and is a simpler drug to administer (26) .
Chloroquine is not usually thought of as an intestinal drug; it is a systemic amebacide. It has little effect on intestinal infections. The South African group could only get a 10~o cure rate with this particular drug (21) .
Paromomycin is a nonabsorbale, broad spectrum antibiotic isolated from streptomyces. In addition to its antibacterial properties, it is thought to have an antiamebal action. The use of antibiotics in amebiasis is based on an indirect effect of the antibiotic altering the bacterial flora and modifying the apparently delicate ameba-bacterial relationship. Any direct amebacidal action of this particular drug then is a furth_r wduable factor. Two grams a day for 10 days is the usual dose. The toxicity is that common to all antibiotics that disturb the intestinal flora. It is an effective therapy with a success rate of 80~,. It is more effective in acute intestinal disease than in the carrier state (26, 27) .
Tetracycline is representative of the absorbable broad spectrum agents. The dosage commonly employed was 0.5 g four times a day for 10 days. Until recently, the broad spectrum antibiotics have been the drugs of choice for acute intestinal amebiasis in most tropical areas. They are oral agents with a high degree of effectiveness in comparison with emetine, and with a low toxicity. However, their cost may be high. Relapse rates are also high. This is a late relapse, suggesting that the drug effect may I)e more suppressive than curative. For this reason, it is often given in conjunction with a contact anaebacide such as diodoquin. The immediate success rate is 97°{, in the hands of the South African group (26) . Toxicity includes alteration of the intestinal flora and sensitivity reactions. There are also problems with the deposition of the drug in the enamel of the teeth in children, though a short course should not cause this problem. The use of outdated tetracycline should be completely preventable. Clearly, tetracycline is the drug that any new preparation will have to beat in terms of its utility. Factors of cost, mode o1 administration and toxicity are its weak points.
This brings us to metronidazole. At this time, metronidazole is the most effective, least toxic intestinal amebacide available (28) (29) (30) (31) (32) . It is coupled with a potent systemic action. The effective close remains to 1)e clarified. For acute intestinal infection, the current recommendation is 750 rag, three times a day for 5 (lays (29) . A number of regimens using fewer, larger doses have been stu(lied, and are of particular interest when patients will not return for followup. In our environment, this particular approach, a 5-day course, has so few side effects that it is probably the program of choice. The toxicity includes nausea, vomitlug, dizziness, urticaria and a metallic taste in the month usually with higher doses of the drug. There is an untoward reaction after ingestion of alcohol, which has been reported in some patients who receive the drug. It is a nitroimadozole derivative, it does cause leucopenia, and at this time it is contraindicated in blood dyscrasias. It has a central nervous system toxicity in some animals; at this time. it is %lt that it should l)e withheld in patients with organic central nervous system iUness until this area of the drug activity is better understood. Since the range of toxicity is different, it is difficult to compare it with that of emetine an(1 tetracycline; however, the impression is that the toxicity of metronidazole is milder. As an anaebacidal therapy, it appears to have a clear advantage since relapse rates seen with tetracycline have not been reported. Success rates from 86 to 955~ ~ have been consistently reported. Currently it is the drug of choice.
In tile treatment of amebic abscess, emetine is once again the yardstick against which the other drugs must be measured. The success rate of emetine in the hands of the South African group from whom these data have been derived is 100~o (33) , but it should be noted that these figures are for a double course of the drug. With a single course of the drug, they have a relapse rate of 7.7~. The toxicity' is the same as for its use in intestinal disease.
Chloroquine is a highly, effective drug in systemic amebiasis with a substantial advantage over emetine because of its lower toxicity. Given as a single course of 150 mg two times a day over 30 days after a loading dose, the success rate for chloroquine ,-oe (33) . An absolute failure here alone is t2/o is an instance where a patient's condition deteriorates during the 30-day course on the drug, and it is thought that one must then intervene with emetine. The toxicity includes retinal lesions, skin eruptions, including a psoriatic-like eruption, nausea, dizziness, and in a few people, psychic stimulation. However, chloroquine used in this manner rarely presents a significant toxicity problem. The failure of either emetine or chloroquine alone to give 100% success with a single course of administration prompted the South African group to try combination therapy. With this approach, a single course of each drug is administered concurrently. Success with this regimen is excellent, and until recently, this has been the therapy of choice for amebic abscesses (34) .
Metroniadazole then came on the scene. Once again this proved to be the most potent, least toxic drug for systemic ameba infection that has yet been described. The minimum dose in systemic amebiasis has yet to be determined. The South Africans use 800 mg three times a (lay for 5 days. The best local equivalent is 75(1 mg sin(c the drug is formulated in a 250-rag tablet in this country, aud ill :1 200-lUg tab.or outside of this country. In the South African group, and in others, this has been 100~{0 effective in treating amebic ab:~cess (28, 29) . In the few patients we have had an opportunity to treat at the University of Michigan, we also have had 100~ success. Single large doses have been trie:l with success but with some attendant toxicity, usually in the form of vomiting at the dose level administered.
In summary, what we treat, whom we treat, with what agent we treat ameba infection all have undergone recent and substantial change. For those who have been separated from the evolution of recent information, amebiasis presented in this way at this time has the appearance of a new disease.
